Emperador Devy M, Mazzola Laura T, Kelly-Cirino Cassandra
Foundation for Innovative and New Diagnostics, Geneva, Switzerland.
Foundation for Innovative and New Diagnostics, San Francisco, California, United States.
Afr J Lab Med. 2020 Sep 28;9(2):1017. doi: 10.4102/ajlm.v9i2.1017. eCollection 2020.
Diagnostic development for outbreak pathogens has typically followed a disease-specific reactive rather than proactive response. Given the diversity of outbreak pathogens, particularly those prioritised by the World Health Organization Research and Development Blueprint, a more flexible and proactive approach to epidemic preparedness is needed to expand access to critical molecular diagnostic tests in peripheral and resource-constrained deployment settings.
New and more sustainable directives are needed to spur the development of high-quality products, particularly for epidemics more often found in low- and middle-income countries. To leverage and de-risk the development process, we present the benefits and challenges of an open-source business model for co-development of molecular diagnostic tests for decentralised settings.
We identify key outbreak pathogens that are available only for testing in high infrastructure laboratories and compare in-country installed base platforms that could be leveraged for menu expansion. Key strengths and challenges for development are highlighted for both platform and assay developers, with discussion of how to leverage and de-risk the process through an open-source development model.
Depending on the specific partner strengths, options for partnership roles are presented. The proposed open-source business model addresses the particular challenges in the detection of outbreak- and epidemic-prone pathogens in low- and middle-income countries, reduces development and deployment risks to support outbreak response, strengthens diagnostic capacity and creates a viable market for product developers.
We hope this model for a collaborative and open-source approach for molecular diagnostics serves to encourage stakeholders to consider co-development partnerships to improve outbreak preparedness and epidemic/pandemic response.
针对疫情病原体的诊断开发通常遵循针对特定疾病的被动反应而非主动应对方式。鉴于疫情病原体的多样性,尤其是世界卫生组织研发蓝图所优先考虑的那些病原体,需要一种更灵活主动的疫情防范方法,以扩大在周边地区和资源有限的部署环境中获得关键分子诊断检测的机会。
需要新的、更具可持续性的指令来推动高质量产品的开发,特别是针对低收入和中等收入国家更常见的疫情。为了利用开发过程并降低风险,我们阐述了一种开源商业模式在为分散式环境共同开发分子诊断检测方面的益处和挑战。
我们确定仅在高基础设施实验室才可进行检测的关键疫情病原体,并比较可用于扩展检测项目菜单的国内现有平台。针对平台和检测开发者,突出了开发过程中的关键优势和挑战,并讨论了如何通过开源开发模式利用该过程并降低风险。
根据合作伙伴的具体优势,介绍了合作伙伴角色的选择。所提议的开源商业模式解决了低收入和中等收入国家在检测易引发疫情的病原体方面的特殊挑战,降低了开发和部署风险以支持疫情应对,增强了诊断能力,并为产品开发者创造了一个可行的市场。
我们希望这种分子诊断的协作式开源方法模式能够鼓励利益相关者考虑共同开发伙伴关系,以改善疫情防范以及应对流行病/大流行的能力。